For example, patients with Philadelphia chromosome (Ph) translocation, PDGFRB-rearrangement, MEF2D-rearrangement, KMT2A-rearrangement, TP53 mutation, and TCF3-HLF are classified into high- or very high-risk ALL subgroups (4). This evidence concerns the gene MEF2D and acute lymphoblastic leukemia.